Thoratec Shares Plummet 26% As 2014 Outlook Slashed, Q2 Profit Declines

Posted by Unknown on Wednesday, August 6, 2014

... of CE Mark trials for both HeartMate III and HeartMate PHP, while HeartMate III also received conditional approval from FDA to begin the U.S. trial.

more

{ 0 comments... » Thoratec Shares Plummet 26% As 2014 Outlook Slashed, Q2 Profit Declines read them below or add one }

Post a Comment

Popular Posts